 |
인쇄하기
취소
|
Daewoong, Peptron Agree on Joint Development of Acromegaly Treatment
Daewoong Pharmaceutical announced on December 30th that it has made a joint development agreement with Peptron Inc., a local biotech venture company, to collaborate on developing the treatment for acromegaly with octreotide as an active ingredient.
Octreotide is a synthetic protein which helps decrease the production of many substances in the body, including growth hormone. Thus, the develo...
Octreotide is a synthetic protein which helps decrease the production of many substances in the body, including growth hormone. Thus, the develo...
Fees
- Email service daily and homepage access.
- $300 per month.
- 5 Email holders per each company.
- Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.